Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (75.0%)
Phase 41 (25.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

NCT01336166
completedphase_4

Safety of H1N1 Influenza Vaccination in Pregnant Women

NCT01842997
completedphase_2

Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

NCT01494740
unknownphase_2

Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients

NCT01055990

Clinical Trials (4)

Showing 4 of 4 trials
NCT01336166Phase 2

The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Completed
NCT01842997Phase 4

Safety of H1N1 Influenza Vaccination in Pregnant Women

Completed
NCT01494740Phase 2

Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

Completed
NCT01055990Phase 2

Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4